Brian T Hill

List of Publications by Year in Descending Order

153 papers	5,636 citations	25 h-index	73 g-index
160 ext. papers	7,851 ext. citations	4.6 avg, IF	5.22 L-index

#	Paper	IF	Citations
153	The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study.. *Cancers*, **2022**, 14,	6.6	1
152	Evaluation of pre-transplant risk assessments in allogeneic hematopoietic cell transplant.. *Bone Marrow Transplantation*, **2022**,	4.4	
151	Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. *Blood*, **2021**, 137, 1832-1835	2.2	16
150	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. *Haematologica*, **2021**, 106, 284-287	6.6	1
149	Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients ≥65 Years Receiving Bendamustine-Rituximab. *Blood*, **2021**, 138, 3517-3517	2.2	0
148	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. *Blood*, **2021**, 138, 2628-2628	2.2	5
147	Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry. *Blood*, **2021**, 138, 2637-2637	2.2	0
146	Quantitative Assessment of the Evolution of Therapeutic Target Antigen Expression Level in Diffuse Large B-Cell Lymphoma in Response to Treatment. *Blood*, **2021**, 138, 4367-4367	2.2	
145	Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. *Blood*, **2021**, 138, 165-165	2.2	0
144	Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. *Blood*, **2021**, 138, 1451-1451	2.2	
143	Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium. *Blood*, **2021**, 138, 744-744	2.2	3
142	A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects with B-Cell Malignancies. *Blood*, **2021**, 138, 3868-3868	2.2	1
141	A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥70 Years of Age) with Chronic Lymphocytic Leukemia (CLL). *Blood*, **2021**, 138, 3728-3728	2.2	2
140	Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. *Blood*, **2021**, 138, 429-429	2.2	2
139	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. *Blood*, **2021**, 138, 529-529	2.2	1
138	High Rates of Undetectable Minimal Residual Disease Remissions with Time-Limited Bendamustine, Rituximab, and Venetoclax (BR-VR) in Untreated Chronic Lymphocytic Leukemia (CLL). *Blood*, **2021**, 138, 1555-1555	2.2	0
137	Long-Term Outcomes of Patients with Large B-Cell Lymphoma Treated with Standard-of-Care Axicabtagene Ciloleucel: Results from the US Lymphoma CAR-T Cell Consortium. *Blood*, **2021**, 138, 3826-3826	2.2	0

136	Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Evolve CLL/SLL Study (SWOG S1925; NCT#04269902). *Blood*, **2021**, 138, 2630-2630	2.2	1
135	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. *Haematologica*, **2021**, 106, 2845-2852	6.6	7
134	Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis. *Leukemia and Lymphoma*, **2021**, 62, 1344-1352	1.9	3
133	Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma. *Expert Opinion on Biological Therapy*, **2021**, 21, 435-441	5.4	13
132	Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. *Future Oncology*, **2021**, 17, 1295-1310	3.6	1
131	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. *European Journal of Haematology*, **2021**, 107, 301-310	3.8	1
130	Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. *Transplantation and Cellular Therapy*, **2021**, 27, 46-52		8
129	A pilot clinical trial of oral tetrahydrouridine/decitabine for noncytotoxic epigenetic therapy of chemoresistant lymphoid malignancies. *Seminars in Hematology*, **2021**, 58, 35-44	4	4
128	Late occurrence of progressive multifocal leukoencephalopathy after anti-CD19 chimeric antigen receptor T-cell therapy. *European Journal of Haematology*, **2021**, 106, 584-588	3.8	4
127	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis. *Clinical Lymphoma, Myeloma and Leukemia*, **2021**, 21, 170-175	2	5
126	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. *Bone Marrow Transplantation*, **2021**, 56, 2911-2921	4.4	2
125	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. *Blood Advances*, **2021**, 5, 3623-3632	7.8	1
124	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. *Blood*, **2021**,	2.2	6
123	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. *Transplantation and Cellular Therapy*, **2021**, 27, 720-728		4
122	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. *Blood Advances*, **2021**, 5, 5179-5189	7.8	0
121	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. *British Journal of Haematology*, **2021**, 195, 757-763	4.5	2
120	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. *Leukemia and Lymphoma*, **2021**, 1-9	1.9	1
119	Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. *Lancet Haematology,the*, **2020**, 7, e511-e522	14.6	97

118	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. *Clinical Cancer Research*, **2020**, 26, 3589-3596	12.9	43
117	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *New England Journal of Medicine*, **2020**, 382, 1331-1342	59.2	448
116	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. *British Journal of Haematology*, **2020**, 189, 318-322	4.5	3
115	The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. *Journal of Critical Care*, **2020**, 58, 58-64	4	19
114	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. *Blood*, **2020**, 136, 34-35	2.2	
113	Unbiased Metabolomic Screening Reveals Pre-Existing Plasma Signatures in Large B-Cell Lymphoma Patients Treated with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cells: Association with Cytokine Release Syndrome (CRS) and Neurotoxicity (ICANS). *Blood*, **2020**, 136, 42-43	2.2	0
112	Resource Utilization and Factors Prolonging Hospitalization for Patients with Relapsed and Refractory Large B-Cell Lymphoma Receiving Tisagenlecleucel Versus Axicabtagene Ciloleucel. *Blood*, **2020**, 136, 38-39	2.2	2
111	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. *Blood*, **2020**, 136, 15-16	2.2	
110	Outcomes of Active Surveillance Versus Initial Treatment for Nodular Lymphocyte Predominant Hodgkin Lymphoma: A National Cancer Database (NCDB) Analysis of 2,480 Patients. *Blood*, **2020**, 136, 29-30	2.2	
109	Gene Expression and Epigenetic Analysis in Relapsed/Refractory Diffuse Large B Cell Lymphoma Provides Insights into Evolution of Treatment Resistance to R-CHOP. *Blood*, **2020**, 136, 26-26	2.2	1
108	Patterns and Risk of CNS Recurrence after R-EPOCH Treatment for Double/Triple Hit Lymphoma. *Blood*, **2020**, 136, 24-25	2.2	0
107	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. *Blood*, **2020**, 136, 5-6	2.2	
106	Integrative DNA Methylation and Gene Expression Analysis Reveals Candidate Biomarkers Associated with Dichotomized Response to Chemoimmunotherapy in Diffuse Large B-Cell Lymphoma. *Blood*, **2020**, 136, 22-22	2.2	
105	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI) Predicts Survival and Tolerance of Ibrutinib Therapy in Patients with CLL: A Multicenter Retrospective Cohort Study. *Blood*, **2020**, 136, 1-3	2.2	
104	Results of a Phase I Trial of Lenalidomide, Rituximab (R2) and Ixazomib for Frontline Treatment of High Risk Follicular and Indolent Non-Hodgkin Lymphoma. *Blood*, **2020**, 136, 1-2	2.2	1
103	A Multi-Center Analysis of the Impact of Dose Level of R-EPOCH on Outcomes of Patients with Double/Triple-Hit B-Cell Lymphoma. *Blood*, **2020**, 136, 32-34	2.2	0
102	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2020**, 18, 185-217	7.3	14
101	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. *British Journal of Haematology*, **2020**, 188, 918-923	4.5	10

100	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. *Cancer*, **2020**, 126, 293-303	6.4	11
99	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. *Hematology/ Oncology and Stem Cell Therapy*, **2020**, 13, 32-39	2.7	5
98	Descriptive comparison of hospital formulary decisions with published oncology valuation methods. *Journal of Oncology Pharmacy Practice*, **2020**, 26, 891-905	1.7	
97	Therapeutic Dose Monitoring of Busulfan Is Associated with Reduced Risk of Relapse in Non-Hodgkin Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 262-271	4.7	5
96	Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma. *Bone Marrow Transplantation*, **2020**, 55, 1184-1187	4.4	19
95	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. *Blood Advances*, **2020**, 4, 253-262	7.8	16
94	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 12-20	7.3	28
93	The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population. *Leukemia and Lymphoma*, **2019**, 60, 2899-2908	1.9	4
92	One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, 467-476	7.1	4
91	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. *Clinical Cancer Research*, **2019**, 25, 4264-4270	12.9	37
90	Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States. *British Journal of Haematology*, **2019**, 186, 255-262	4.5	10
89	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. *Journal of Clinical Oncology*, **2019**, 37, 471-480	2.2	44
88	The Emerging Role of Minimal Residual Disease Testing in Diffuse Large B-Cell Lymphoma. *Current Oncology Reports*, **2019**, 21, 44	6.3	5
87	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphomas. *Bone Marrow Transplantation*, **2019**, 54, 1553-1561	4.4	3
86	Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy. *Biology of Blood and Marrow Transplantation*, **2019**, 25, e344-e351	4.7	32
85	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. *Oncologist*, **2019**, 24, e1236-e1250	5.7	20
84	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. *Clinical Cancer Research*, **2019**, 25, 5143-5155	12.9	6
83	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 2522-2526	4.7	1

82	Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study. *Mycoses*, **2019**, 62, 1140-1147	5.2	38
81	A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2019**, 134, 360-360	2.2	8
80	Targeted Treatment and Survival Following Relapse after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia and MDS in the Contemporary Era. *Blood*, **2019**, 134, 4567-4567	2.2	2
79	Comorbidities Predict Inferior Survival in Patients Receiving CAR T-Cell Therapy for Relapsed/Refractory DLBCL: A Multicenter Retrospective Analysis. *Blood*, **2019**, 134, 780-780	2.2	7
78	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. *Blood*, **2019**, 134, 754-754	2.2	16
77	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. *Blood*, **2019**, 134, 753-753	2.2	6
76	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. *Blood*, **2019**, 134, 763-763	2.2	20
75	Characteristics and Outcomes of Patients Receiving Bridging Therapy While Awaiting Manufacture of Standard of Care Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. *Blood*, **2019**, 134, 245-245	2.2	24
74	Survival Outcomes in Patients with Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma According to MYD88 Mutation Status. *Blood*, **2019**, 134, 5248-5248	2.2	0
73	Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation. *Blood*, **2019**, 134, 1226-1226	2.2	
72	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 1107-1115	4.7	6
71	Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. *Blood Advances*, **2019**, 3, 132-135	7.8	9
70	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. *Blood Advances*, **2019**, 3, 1568-1573	7.8	18
69	Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. *British Journal of Haematology*, **2019**, 184, 524-535	4.5	16
68	Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, 48-52	2	
67	Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. *Leukemia and Lymphoma*, **2019**, 60, 1972-1977	1.9	19
66	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. *Bone Marrow Transplantation*, **2019**, 54, 775-781	4.4	8
65	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. *Lancet Oncology, The*, **2019**, 20, 31-42	21.7	796

64	Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. *Haematologica*, **2018**, 103, 874-879	6.6	219
63	Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant. *Therapeutic Advances in Hematology*, **2018**, 9, 81-87	5.7	3
62	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1029-1034	4.7	11
61	Cardiac Surgery Outcomes in Patients With Chronic Lymphocytic Leukemia. *Annals of Thoracic Surgery*, **2018**, 105, 1182-1191	2.7	3
60	A phase I trial of bortezomib in combination with everolimus for treatment of relapsed/refractory non-Hodgkin lymphoma. *Leukemia and Lymphoma*, **2018**, 59, 690-694	1.9	3
59	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 581-586	4.7	3
58	Prognostic value of pre-transplant PET/CT in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. *Leukemia and Lymphoma*, **2018**, 59, 1195-1201	1.9	10
57	Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. *American Journal of Hematology*, **2018**, 93, 1394-1401	7.1	37
56	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. *Haematologica*, **2018**, 103, 1511-1517	6.6	91
55	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. *Blood*, **2018**, 132, 2967-2967	2.2	11
54	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. *Blood*, **2018**, 132, 91-91	2.2	64
53	Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience. *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, e95-e102	2	3
52	Impact of HLA Alleles on Outcomes of Allogeneic Transplantation for B Cell Non-Hodgkin Lymphomas: A Center for International Blood and Marrow Transplant Research Analysis. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 827-831	4.7	1
51	Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. *Cancer*, **2018**, 124, 816-825	6.4	28
50	Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 1567-1572	4.7	15
49	Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. *American Journal of Hematology*, **2017**, 92, 989-996	7.1	22
48	Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax. *Clinical Pharmacokinetics*, **2017**, 56, 1255-1266	6.2	9
47	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. *British Journal of Haematology*, **2017**, 176, 618-628	4.5	30

46	Extranodal Marginal Zone Lymphoma of Ocular Adnexa: Outcomes following Radiation Therapy. *Ocular Oncology and Pathology*, **2017**, 3, 181-187	1.6	16
45	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. *Journal of Clinical Oncology*, **2017**, 35, 2260-2267	2.2	89
44	Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population. *Clinical Lymphoma, Myeloma and Leukemia*, **2017**, 17, 857-862	2	9
43	A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib. *Blood*, **2017**, 130, 1676-1679	2.2	20
42	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. *New England Journal of Medicine*, **2017**, 377, 2531-2544	59.2	2326
41	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2017**, 15, 1414-1427	7.3	18
40	Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning. *British Journal of Haematology*, **2017**, 179, 674-676	4.5	5
39	Phase I study of single-agent CC-292, a highly selective Bruton© tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. *Haematologica*, **2016**, 101, e295-8	6.6	54
38	Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era. *British Journal of Haematology*, **2016**, 175, 275-280	4.5	11
37	Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1141-1144	4.7	8
36	Dual expression of MYC and BCL2 proteins predicts worse outcomes in diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2016**, 57, 1640-8	1.9	8
35	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. *Blood*, **2016**, 128, 3222-3222	2.2	16
34	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). *Blood*, **2016**, 128, 4666-4666	2.2	
33	Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas. *Blood and Lymphatic Cancer: Targets and Therapy*, **2016**, 6, 1-6	2.6	7
32	Clinical approach to diffuse large B cell lymphoma. *Blood Reviews*, **2016**, 30, 477-491	11.1	19
31	It© Personal: Achieving Optimal Busulfan Exposure for All Patients. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1149-1150	4.7	
30	Ionizing radiation exposures in treatments of solid neoplasms are not associated with subsequent increased risks of chronic lymphocytic leukemia. *Leukemia Research*, **2016**, 43, 9-12	2.7	9
29	Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1588-1595	4.7	6

28	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 2117-2125	4.7	70
27	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. *American Journal of Hematology*, **2015**, 90, 144-8	7.1	22
26	Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin. *Leukemia and Lymphoma*, **2015**, 56, 1552-3	1.9	12
25	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. *Hematology/ Oncology and Stem Cell Therapy*, **2015**, 8, 115-24	2.7	2
24	Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. *OncoTargets and Therapy*, **2015**, 8, 2391-7	4.4	2
23	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. *Molecular Cancer*, **2015**, 14, 185	42.1	32
22	Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients. *Leukemia and Lymphoma*, **2015**, 56, 293-300	1.9	7
21	Favorable Outcomes in CLL Pts with Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation: Results from a Large Multi-Center Study. *Blood*, **2015**, 126, 719-719	2.2	9
20	Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics. *Oncotarget*, **2015**, 6, 16912-25	3.3	48
19	Targeting mTORC1-mediated metabolic addiction overcomes fludarabine resistance in malignant B cells. *Molecular Cancer Research*, **2014**, 12, 1205-15	6.6	18
18	Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics. *American Journal of Clinical Pathology*, **2014**, 142, 339-46	1.9	26
17	Fine-mapping of HLA associations with chronic lymphocytic leukemia in US populations. *Blood*, **2014**, 124, 2657-65	2.2	24
16	Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL Microenvironment. *Journal of Leukemia (Los Angeles, Calif)*, **2014**, 2,		12
15	Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex system. *British Journal of Haematology*, **2014**, 167, 281-5	4.5	14
14	Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. *Biology of Blood and Marrow Transplantation*, **2013**, 19, 720-4	4.7	30
13	The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. *British Journal of Haematology*, **2013**, 163, 72-80	4.5	20
12	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). *Blood*, **2013**, 122, 1630-1630	2.2	25
11	Phase 2 Study Of Otlertuzumab (TRU-016), An Anti-CD37 ADAPTIRTM Protein, In Combination With Bendamustine Vs Bendamustine Alone In Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). *Blood*, **2013**, 122, 2860-2860	2.2	5

10	Pulmonary involvement by chronic lymphocytic leukemia/small lymphocytic lymphoma is a specific pathologic finding independent of inflammatory infiltration. *Leukemia and Lymphoma*, **2012**, 53, 589-95	1.9	15
9	Clinical implications of the molecular subtypes of diffuse large B-cell lymphoma. *Leukemia and Lymphoma*, **2012**, 53, 763-9	1.9	14
8	Impact of Mutations in the Spliceosome Machinery and Ring Sideroblasts in Patients with Myeloid Malignancies Who Received Conventional Chemotherapy or Allogeneic Hematopoietic Cell Transplantation. *Blood*, **2012**, 120, 1973-1973	2.2	1
7	Molecular Subtype Characterization of Formalin-Fixed, Paraffin-Embedded Diffuse Large B-Cell Lymphoma Samples on the Iceplex System.. *Blood*, **2012**, 120, 2705-2705	2.2	
6	Tandem Autologous Hematopoietic Progenitor Cell Transplantation (AHPCT) for High-Risk Hodgkin Lymphoma: Mature Results of a Prospective Trial. *Blood*, **2012**, 120, 1990-1990	2.2	
5	The PI3K Inhibitor GS-1101 (CAL-101) Synergistically Potentiates HDAC-Induced Proliferation Inhibition and Apoptosis Through the Activation of JNK in Lymphoma Cells. *Blood*, **2012**, 120, 3714-3714	2.2	
4	The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. *British Journal of Haematology*, **2011**, 152, 561-9	4.5	26
3	Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma. *Leukemia and Lymphoma*, **2011**, 52, 986-93	1.9	19
2	Nonmyeloablative second transplants are associated with lower nonrelapse mortality and superior survival than myeloablative second transplants. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1738-46	4.7	10
1	Acute myeloid leukemia: when to transplant in first complete remission. *Current Hematologic Malignancy Reports*, **2010**, 5, 101-8	4.4	9